Cancer Monoclonal Antibodies Market 2027 By Types, Therapies, Application, and Geography | The Insight Partners

Cancer Monoclonal Antibodies Market to 2027 - Global Analysis and Forecasts by Types (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies); Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others); Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others), and Geography

Report Code: TIPRE00004907 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming
MARKET INTRODUCTION
Cancer is the fatal disease caused due to mutation in the DNA of cell. This mutation causes the cell to replicated innumerable number of times. Monoclonal antibodies are derived from immunological cells of single parental origin. The chemotherapy and radiotherapy are traditional cancer treatment options but they have side effects such as toxicity. Monoclonal antibodies provides a new and efficient way of cancer cell specific treatment which are targeted to individual cells. They are used due to characteristics of specificity and less toxicity

MARKET DYNAMICS
The cancer monoclonal antibodies market is anticipated to grow in the forecast period owing to increasing occurrence of cancer patients. Furthermore, the rising investment in research and development of genomic studies and increasing advancements in preference towards specificity of monoclonal antibodies specific to the target are few more factors driving the growth of cancer monoclonal antibodies market the forecast period.

MARKET SCOPE
The "Global Cancer Monoclonal Antibodies Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of cancer monoclonal antibodies market with detailed market segmentation by types, therapies, application and geography. The global cancer monoclonal antibodies market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading cancer monoclonal antibodies market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global cancer monoclonal antibodies market is segmented on the basis of types, therapies and application. Based on types, the market is classified as murine antibodies, chimeric antibodies, humanized antibodies. On the basis of therapies, the market is divided into bevacizumab (avastin), rituximab (rituxan), trastuzumab (herceptin), cetuximab (erbitux), panitumumab (vectibix) and others. Based on application, the cancer monoclonal antibodies market is classified as breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global cancer monoclonal antibodies market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The cancer monoclonal antibodies market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting cancer monoclonal antibodies market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the cancer monoclonal antibodies market in these regions.

MARKET PLAYERS
The reports cover key developments in the cancer monoclonal antibodies market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from cancer monoclonal antibodies market are anticipated to lucrative growth opportunities in the future with the rising demand for cancer monoclonal antibodies market in the global market. Below mentioned is the list of few companies engaged in the cancer monoclonal antibodies market.

The report also includes the profiles of key cancer monoclonal antibodies market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Amgen Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GlaxoSmithKline plc.
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Pfizer Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cancer Monoclonal Antibodies Market - By Types
1.3.2 Cancer Monoclonal Antibodies Market - By Therapies
1.3.3 Cancer Monoclonal Antibodies Market - By Application
1.3.4 Cancer Monoclonal Antibodies Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CANCER MONOCLONAL ANTIBODIES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CANCER MONOCLONAL ANTIBODIES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CANCER MONOCLONAL ANTIBODIES MARKET - GLOBAL MARKET ANALYSIS
6.1. CANCER MONOCLONAL ANTIBODIES - GLOBAL MARKET OVERVIEW
6.2. CANCER MONOCLONAL ANTIBODIES - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CANCER MONOCLONAL ANTIBODIES MARKET - REVENUE AND FORECASTS TO 2027 - TYPES
7.1. OVERVIEW
7.2. TYPES MARKET FORECASTS AND ANALYSIS
7.3. MURINE ANTIBODIES
7.3.1. Overview
7.3.2. Murine Antibodies Market Forecast and Analysis
7.4. CHIMERIC ANTIBODIES
7.4.1. Overview
7.4.2. Chimeric Antibodies Market Forecast and Analysis
7.5. HUMANIZED ANTIBODIES
7.5.1. Overview
7.5.2. Humanized Antibodies Market Forecast and Analysis
8. CANCER MONOCLONAL ANTIBODIES MARKET - REVENUE AND FORECASTS TO 2027 - THERAPIES
8.1. OVERVIEW
8.2. THERAPIES MARKET FORECASTS AND ANALYSIS
8.3. BEVACIZUMAB (AVASTIN)
8.3.1. Overview
8.3.2. Bevacizumab (Avastin) Market Forecast and Analysis
8.4. RITUXIMAB (RITUXAN)
8.4.1. Overview
8.4.2. Rituximab (Rituxan) Market Forecast and Analysis
8.5. TRASTUZUMAB (HERCEPTIN)
8.5.1. Overview
8.5.2. Trastuzumab (Herceptin) Market Forecast and Analysis
8.6. CETUXIMAB (ERBITUX)
8.6.1. Overview
8.6.2. Cetuximab (Erbitux) Market Forecast and Analysis
8.7. PANITUMUMAB (VECTIBIX)
8.7.1. Overview
8.7.2. Panitumumab (Vectibix) Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. CANCER MONOCLONAL ANTIBODIES MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. BREAST CANCER
9.3.1. Overview
9.3.2. Breast Cancer Market Forecast and Analysis
9.4. BLOOD CANCER
9.4.1. Overview
9.4.2. Blood Cancer Market Forecast and Analysis
9.5. LIVER CANCER
9.5.1. Overview
9.5.2. Liver Cancer Market Forecast and Analysis
9.6. BRAIN CANCER
9.6.1. Overview
9.6.2. Brain Cancer Market Forecast and Analysis
9.7. COLORECTAL CANCER
9.7.1. Overview
9.7.2. Colorectal Cancer Market Forecast and Analysis
9.8. OTHERS
9.8.1. Overview
9.8.2. Others Market Forecast and Analysis
10. CANCER MONOCLONAL ANTIBODIES MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Cancer Monoclonal Antibodies Market Overview
10.1.2 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.1.3 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Types
10.1.4 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.1.5 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.1.6 North America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.1.6.1 United States Cancer Monoclonal Antibodies Market
10.1.6.1.1 United States Cancer Monoclonal Antibodies Market by Types
10.1.6.1.2 United States Cancer Monoclonal Antibodies Market by Therapies
10.1.6.1.3 United States Cancer Monoclonal Antibodies Market by Application
10.1.6.2 Canada Cancer Monoclonal Antibodies Market
10.1.6.2.1 Canada Cancer Monoclonal Antibodies Market by Types
10.1.6.2.2 Canada Cancer Monoclonal Antibodies Market by Therapies
10.1.6.2.3 Canada Cancer Monoclonal Antibodies Market by Application
10.1.6.3 Mexico Cancer Monoclonal Antibodies Market
10.1.6.3.1 Mexico Cancer Monoclonal Antibodies Market by Types
10.1.6.3.2 Mexico Cancer Monoclonal Antibodies Market by Therapies
10.1.6.3.3 Mexico Cancer Monoclonal Antibodies Market by Application
10.2. EUROPE
10.2.1 Europe Cancer Monoclonal Antibodies Market Overview
10.2.2 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.2.3 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Types
10.2.4 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.2.5 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.2.6 Europe Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Cancer Monoclonal Antibodies Market
10.2.6.1.1 Germany Cancer Monoclonal Antibodies Market by Types
10.2.6.1.2 Germany Cancer Monoclonal Antibodies Market by Therapies
10.2.6.1.3 Germany Cancer Monoclonal Antibodies Market by Application
10.2.6.2 France Cancer Monoclonal Antibodies Market
10.2.6.2.1 France Cancer Monoclonal Antibodies Market by Types
10.2.6.2.2 France Cancer Monoclonal Antibodies Market by Therapies
10.2.6.2.3 France Cancer Monoclonal Antibodies Market by Application
10.2.6.3 Italy Cancer Monoclonal Antibodies Market
10.2.6.3.1 Italy Cancer Monoclonal Antibodies Market by Types
10.2.6.3.2 Italy Cancer Monoclonal Antibodies Market by Therapies
10.2.6.3.3 Italy Cancer Monoclonal Antibodies Market by Application
10.2.6.4 Spain Cancer Monoclonal Antibodies Market
10.2.6.4.1 Spain Cancer Monoclonal Antibodies Market by Types
10.2.6.4.2 Spain Cancer Monoclonal Antibodies Market by Therapies
10.2.6.4.3 Spain Cancer Monoclonal Antibodies Market by Application
10.2.6.5 United Kingdom Cancer Monoclonal Antibodies Market
10.2.6.5.1 United Kingdom Cancer Monoclonal Antibodies Market by Types
10.2.6.5.2 United Kingdom Cancer Monoclonal Antibodies Market by Therapies
10.2.6.5.3 United Kingdom Cancer Monoclonal Antibodies Market by Application
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Cancer Monoclonal Antibodies Market Overview
10.3.2 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.3.3 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Types
10.3.4 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.3.5 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.3.6 Asia-Pacific Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Cancer Monoclonal Antibodies Market
10.3.6.1.1 Australia Cancer Monoclonal Antibodies Market by Types
10.3.6.1.2 Australia Cancer Monoclonal Antibodies Market by Therapies
10.3.6.1.3 Australia Cancer Monoclonal Antibodies Market by Application
10.3.6.2 China Cancer Monoclonal Antibodies Market
10.3.6.2.1 China Cancer Monoclonal Antibodies Market by Types
10.3.6.2.2 China Cancer Monoclonal Antibodies Market by Therapies
10.3.6.2.3 China Cancer Monoclonal Antibodies Market by Application
10.3.6.3 India Cancer Monoclonal Antibodies Market
10.3.6.3.1 India Cancer Monoclonal Antibodies Market by Types
10.3.6.3.2 India Cancer Monoclonal Antibodies Market by Therapies
10.3.6.3.3 India Cancer Monoclonal Antibodies Market by Application
10.3.6.4 Japan Cancer Monoclonal Antibodies Market
10.3.6.4.1 Japan Cancer Monoclonal Antibodies Market by Types
10.3.6.4.2 Japan Cancer Monoclonal Antibodies Market by Therapies
10.3.6.4.3 Japan Cancer Monoclonal Antibodies Market by Application
10.3.6.5 South Korea Cancer Monoclonal Antibodies Market
10.3.6.5.1 South Korea Cancer Monoclonal Antibodies Market by Types
10.3.6.5.2 South Korea Cancer Monoclonal Antibodies Market by Therapies
10.3.6.5.3 South Korea Cancer Monoclonal Antibodies Market by Application
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Cancer Monoclonal Antibodies Market Overview
10.4.2 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.4.3 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Types
10.4.4 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.4.5 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.4.6 Middle East and Africa Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Cancer Monoclonal Antibodies Market
10.4.6.1.1 South Africa Cancer Monoclonal Antibodies Market by Types
10.4.6.1.2 South Africa Cancer Monoclonal Antibodies Market by Therapies
10.4.6.1.3 South Africa Cancer Monoclonal Antibodies Market by Application
10.4.6.2 Saudi Arabia Cancer Monoclonal Antibodies Market
10.4.6.2.1 Saudi Arabia Cancer Monoclonal Antibodies Market by Types
10.4.6.2.2 Saudi Arabia Cancer Monoclonal Antibodies Market by Therapies
10.4.6.2.3 Saudi Arabia Cancer Monoclonal Antibodies Market by Application
10.4.6.3 U.A.E Cancer Monoclonal Antibodies Market
10.4.6.3.1 U.A.E Cancer Monoclonal Antibodies Market by Types
10.4.6.3.2 U.A.E Cancer Monoclonal Antibodies Market by Therapies
10.4.6.3.3 U.A.E Cancer Monoclonal Antibodies Market by Application
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Cancer Monoclonal Antibodies Market Overview
10.5.2 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis
10.5.3 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Types
10.5.4 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Therapies
10.5.5 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Application
10.5.6 South and Central America Cancer Monoclonal Antibodies Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Cancer Monoclonal Antibodies Market
10.5.6.1.1 Brazil Cancer Monoclonal Antibodies Market by Types
10.5.6.1.2 Brazil Cancer Monoclonal Antibodies Market by Therapies
10.5.6.1.3 Brazil Cancer Monoclonal Antibodies Market by Application
10.5.6.2 Argentina Cancer Monoclonal Antibodies Market
10.5.6.2.1 Argentina Cancer Monoclonal Antibodies Market by Types
10.5.6.2.2 Argentina Cancer Monoclonal Antibodies Market by Therapies
10.5.6.2.3 Argentina Cancer Monoclonal Antibodies Market by Application
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CANCER MONOCLONAL ANTIBODIES MARKET, KEY COMPANY PROFILES
12.1. AMGEN INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. THERMO FISHER SCIENTIFIC INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. F. HOFFMANN-LA ROCHE LTD
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. GENMAB A/S
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. JOHNSON AND JOHNSON SERVICES, INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SEATTLE GENETICS, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SPECTRUM PHARMACEUTICALS, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PFIZER INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Amgen Inc.
2. Thermo Fisher Scientific Inc.
3. F. Hoffmann-La Roche Ltd
4. Genmab A/S
5. GlaxoSmithKline plc.
6. Johnson and Johnson Services, Inc.
7. Novartis AG
8. Seattle Genetics, Inc.
9. Spectrum Pharmaceuticals, Inc.
10. Pfizer Inc.